Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citation
Cited by
Items 301–400 of 1,000
Mapping Physical Tumor Microenvironment and Drug Delivery
Nia, H. T., Munn, L. L., & Jain, R. K. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3724 · Cited by 56
“When solid stress is reduced via antifibrotic treatments, drugdelivery increases through decompression of blood vessels (5).”
BackgroundSelf-citationModulating cancer mechanopathology to restore vascular function and enhance immunotherapy
Mpekris, F., Panagi, M., Charalambous, A., Voutouri, C., & Stylianopoulos, T. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101626 · Cited by 78
“95 Consequently, this reduction in tumor stiffness and mechanical forces leads to the decompression of tumor blood vessels to some extent, ultimately enhancing vascular perfusion and reducing intratumoral hypoxia.”
Self-citationRacacho, K. J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621812 · Cited by 72
Bai, X., Zhi, X., Zhang, Q., Liang, F., Chen, W., Liang, C., Hu, Q., Sun, X., Zhuang, Z., & Liang, T. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.048 · Cited by 58
Pinter, M., Weinmann, A., Wörns, M.-A., Hucke, F., Bota, S., Marquardt, J. U., Duda, D. G., Jain, R. K., Galle, P. R., Trauner, M., et al. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617695698 · Cited by 55
“In several solid malignancies including cholangiocarcinoma, tumor desmoplasia occurs as a secondary event in response to tumor growth, wherein malignant cells drive stromal fibroblasts to produce and deposit ECM.(27,30,38) In contrast, liver fibrosis and cirrhosis represent a procarcinogenic microenvironment that prom…”
BackgroundSelf-citationA mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
Coppola, S., Carnevale, I., Danen, E. H. J., Peters, G. J., Schmidt, T., Assaraf, Y. G., & Giovannetti, E. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.07.001 · Cited by 60
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions
Jenkins, B. H., Buckingham, J. F., Hanley, C. J., & Thomas, G. J. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108231 · Cited by 57
Gu, L., Zhu, Y., Lee, M., Nguyen, A., Ryujin, N. T., Huang, J. Y., Pandit, S. K., Chamseddine, S., Xiao, L., Mohamed, Y. I., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300706120 · Cited by 58
“Other studies carried out by Rakesh Jain’s group have shown that losartan enhances anticancer drug delivery (34) and down-regulates immunosuppression-associated genes in ovarian and pancreatic cancers when combined with chemo-or radio-therapy (35, 36) and reduced ICI-induced edema in glioblastoma…”
BackgroundKibria, G., Hatakeyama, H., Sato, Y., & Harashima, H. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.05.047 · Cited by 55
“…et al., 2011; Jacobetz et al., 2013; McKee et al., 2006; Stylianopoulos et al., 2012) and the depletion of cancer-475 associated fibroblasts (Chauhan et al., 2013; Stylianopoulos et al., 2012) decompress the tumor vessels, and preferentially enhance the delivery, distribution and…”
Ma, Y., Xia, Z., Ye, C., Lu, C., Zhou, S., Pan, J., Liu, C., Zhang, J., Liu, T., Hu, T., et al. (2019) · Aging · doi:10.18632/aging.102032 · Cited by 54
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23179 · Cited by 63
“Across several preclinical mouse models, losartan treatment resulted in a reduction in intratumoral collagen I levels, lowered the density of αSMA +CAFs, decompressed tumor vessels, and enhanced drug and oxygen delivery to tumors.(53,54) Only one clinical trial has been published to date incorporating losartan into th…”
BackgroundWu, L., Vasilijić, S., Sun, Y., Chen, J., Landegger, L. D., Zhang, Y., Zhou, W., Ren, J. P., Early, S., Yin, Z., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd4816 · Cited by 57
Self-citationLiu, Y., Li, B., Wang, X., Li, G., Shang, R., Yang, J., Wang, J., Zhang, M., Chen, Y., Zhang, Y., et al. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00022 · Cited by 53
Patel, K. R., Doddapaneni, R., Chowdhury, N., Boakye, C. H. A., Behl, G., & Singh, M. S. (2016) · Nanomedicine · doi:10.2217/nnm.16.37 · Cited by 56
Fibrosis and Cancer: Partners in Crime or Opposing Forces?
Cox, T. R., & Erler, J. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.004 · Cited by 57
Sakurai, Y., Hada, T., Yamamoto, S., Kato, A., Mizumura, W., & Harashima, H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.178 · Cited by 53
Probing the physical hallmarks of cancer
Nia, H. T., Munn, L. L., & Jain, R. K. (2025) · Nature Methods · doi:10.1038/s41592-024-02564-4 · Cited by 62
Self-citationAntiangiogenic therapy: Markers of response, “normalization” and resistance
Alaoui‐Lasmaili, K. E., & Faivre‐Fiorina, B. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.001 · Cited by 55
The Mechanical Microenvironment in Breast Cancer
Pratt, S. J. P., Lee, R., & Martin, S. S. (2020) · Cancers · doi:10.3390/cancers12061452 · Cited by 59
“Compressive stress from the high cell proliferation characteristic of tumors can compress blood and lymphatic vasculature [200], and this solid stress induced vessel compression contributes to hypoxia and acts as a barrier to drug delivery in breast tumors [201].”
BackgroundLevin, V. A., Chan, J., Datta, M., Yee, J. L., & Jain, R. K. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2528-3 · Cited by 51
“In addition, since preclinical studies found that ASIs can improve tumor perfusion, reducing tumor hypoxia and enhancing drug delivery [5, 11, 12, 15].”
BackgroundSelf-citationCombination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer
Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51
Wang, X., Ye, N., Chen, X., Xiao, C., Zhang, Z., Deng, Q., Li, S., Li, J., Li, Z., & Yang, X. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101458 · Cited by 52
Patel, K. R., Doddapaneni, R., Sekar, V., Chowdhury, N., & Singh, M. S. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00187 · Cited by 53
Xia, T., He, Q., Shi, K., Wang, Y., Yu, Q., Zhang, L., Zhang, Q., Gao, H., Ma, L., & Liu, J. (2016) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2016.1265553 · Cited by 53
Qian, X., Ge, L., Yuan, K., Li, C., Xu, Z. C., Cai, W., Cheng, R., & Jiang, X. (2019) · Theranostics · doi:10.7150/thno.33470 · Cited by 53
“The decrease of tumor IFP by losartan was associated with reduction of stromal collagen and hyaluronan production, a decrease in the expression of profibrotic signals transforming growth factor (TGF)-β1, connective tissue growth factor (CCN2) and endothelin-1 (ET-1) [10].”
BackgroundMethodInfluentialAngiotensin Inhibition, TGF-β and EMT in Cancer
Pallasch, F. B., & Schumacher, U. (2020) · Cancers · doi:10.3390/cancers12102785 · Cited by 60
A bird’s eye view of fibroblast heterogeneity: A pan‐disease, pan‐cancer perspective
Pradhan, R., Krishnamurty, A. T., Fletcher, A. L., Turley, S. J., & Müller, S. (2021) · Immunological Reviews · doi:10.1111/imr.12990 · Cited by 53
Zhao, Q. S., He, X., Qin, X., Liu, Y., Jiang, H., Wang, J., Wu, S., Zhou, R., Yu, C., Liu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938439 · Cited by 54
“Losartan had the potential to lessen solid stress, decompress the intratumor vessels, enhance oxygen and drug delivery and raise chemotherapy efficacy for solid tumors (21, 31, 32).”
BackgroundMethodResultInfluentialXu, Y., Li, W., Lin, S., Liu, B., Wu, P., & Li, L. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01204-2 · Cited by 55
Bar‐Zion, A., Yin, M., Adam, D., & Foster, F. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0376 · Cited by 50
Zhang, B., Jin, K., Jiang, T., Wang, L., Shen, S., Luo, Z., Tuo, Y., Liu, X., Hu, Y., & Pang, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-09520-7 · Cited by 49
Drobni, Z. D., Michielin, O. A., Quinaglia, T., Zlotoff, D. A., Zubiri, L., Gilman, H. K., Sama, S., Merkely, B. P., Müller, V., Sullivan, R. J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.024 · Cited by 51
Self-citationPrecision Hydrogels for the Study of Cancer Cell Mechanobiology
Sievers, J., Mahajan, V., Welzel, P. B., Werner, C., & Taubenberger, A. V. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202514 · Cited by 53
Ultrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy
Voutouri, C., Mpekris, F., Panagi, M., Krolak, C., Michael, C., Martin, J. D., Averkiou, M. A., & Stylianopoulos, T. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.06.007 · Cited by 51
Self-citationZheng, J., & Hao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1333839 · Cited by 54
Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine
Cassani, M., Fernandes, S., Pagliari, S., Cavalieri, F., Caruso, F., & Forte, G. (2025) · Advanced Science · doi:10.1002/advs.202409898 · Cited by 48
Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer
Hamada, S., Masamune, A., & Shimosegawa, T. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00331 · Cited by 55
“Oral administration of IPI-926, a derivative of cyclopamine successfully depleted desmoplasia in the tumors of KPC mice (Olive et al., 2009).”
BackgroundYamamoto, S., Kato, A., Sakurai, Y., Hada, T., & Harashima, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.010 · Cited by 46
“, found that the amount of collagen I was inversely correlated to the proportion of perfused vessels [46].”
BackgroundPhysical oncology: New targets for nanomedicine
Nicolás‐Boluda, A., Silva, A., Fournel, S., & Gazeau, F. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.014 · Cited by 49
Pancreatic Fibroblast Heterogeneity: From Development to Cancer
Garcia, P. E., Scales, M. K., Allen, B. L., & Pasca di Magliano, M. (2020) · Cells · doi:10.3390/cells9112464 · Cited by 48
“This reduction in ECM led to improved tumor perfusion, and improved survival when combined with chemotherapy [193].”
BackgroundMethodSong, Y., Kim, J.-S., Choi, E. K., Kim, J., Kim, K. M., & Seo, H. R. (2017) · Oncotarget · doi:10.18632/oncotarget.15521 · Cited by 45
“Losartan is an angiotensin II receptor antagonist used mainly to treat high blood pressure and potentiate chemotherapy through improvement of drug delivery, nanotherapeutics in tumor [32, 33].”
BackgroundDepletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer
Buchholz, S., Goetze, R. G., Singh, S. K., Ammer‐Herrmenau, C., Richards, F. M., Jodrell, D. I., Buchholz, M., Michl, P., Ellenrieder, V., Heßmann, E., et al. (2020) · Cancers · doi:10.3390/cancers12071978 · Cited by 48
In silico dynamics of COVID-19 phenotypes for optimizing clinical management
Voutouri, C., Nikmaneshi, M. R., Hardin, C. C., Patel, A. B., Verma, A., Khandekar, M. J., Dutta, S., Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021642118 · Cited by 48
Self-citationPhotosynthetic Microorganisms Coupled Photodynamic Therapy for Enhanced Antitumor Immune Effect
Wang, H., Liu, H., Guo, Y., Zai, W., Li, X., Xiong, W., Zhao, X., Yao, Y., Hu, Y., Zou, Z., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.028 · Cited by 46
Self-citationOvercoming physical stromal barriers to cancer immunotherapy
Chung, S. W., Xie, Y., & Suk, J. S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01036-y · Cited by 54
Liang, D., Liu, L., Zhao, Y., Luo, Z., He, Y., Li, Y., Tang, S., Tang, J., & Chen, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1186712 · Cited by 51
G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer?
Rodrigues-Ferreira, S., & Nahmias, C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00024 · Cited by 47
A Quick Guide to CAF Subtypes in Pancreatic Cancer
Brichkina, A. I., Polo, P., Sharma, S. D., Visestamkul, N., & Lauth, M. (2023) · Cancers · doi:10.3390/cancers15092614 · Cited by 49
Chen, K., Nguyen, N., Huang, T., Lin, Y., Yu, Y., Song, H., Wang, J., Nguyen, V. K., Chen, H., Chu, L., et al. (2023) · Advanced Materials · doi:10.1002/adma.202304735 · Cited by 54
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma
Park, J. A., & Cheung, N. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512520 · Cited by 51
Panagi, M., Mpekris, F., Voutouri, C., Hadjigeorgiou, A. G., Symeonidou, C., Porfyriou, E., Michael, C., Stylianou, A., Martin, J. D., Cabral, H., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0246 · Cited by 53
Self-citationZhu, Y., Chen, J., Chen, C., Tang, R., Xu, J., Shi, S., & Yu, X. (2025) · Biomarker Research · doi:10.1186/s40364-025-00727-9 · Cited by 49
Obstacles to T cell migration in the tumor microenvironment
Nicolas-Boluda, A., & Donnadieu, E. (2019) · Comparative Immunology, Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2018.12.006 · Cited by 43
In vivo compression and imaging in mouse brain to measure the effects of solid stress
Nia, H. T., Datta, M., Seano, G., Zhang, S., Ho, W. W., Roberge, S., Huang, P., Munn, L. L., & Jain, R. K. (2020) · Nature Protocols · doi:10.1038/s41596-020-0328-2 · Cited by 51
Self-citationMolecular cancer cell responses to solid compressive stress and interstitial fluid pressure
Purkayastha, P., Jaiswal, M. K., & Lele, T. P. (2021) · Cytoskeleton · doi:10.1002/cm.21680 · Cited by 51
“The collapse of blood vessels can cause hypoxia (Chauhan et al., 2013; Stylianopoulos et al., 2012) and reduce the efficacy of therapeutic drug delivery (Jain, 2014; Munn & Jain, 2019).”
Winship, A., Sinderen, M. L. V., Donoghue, J. F., Rainczuk, K., & Dimitriadis, E. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0677 · Cited by 45
“Targeting the factors that affect the microenvironment improves treatment delivery and patient outcomes (27).”
BackgroundGammon, L., & Mackenzie, I. C. (2015) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12327 · Cited by 47
Fibrin degradation by rtPA enhances the delivery of nanotherapeutics to A549 tumors in nude mice
Zhang, B., Jiang, T., She, X., Shen, S., Wang, S., Deng, J., Shi, W., Mei, H., Hu, Y., Pang, Z., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.015 · Cited by 44
Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling
Nichols, J. W., Sakurai, Y., Harashima, H., & Bae, Y. H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.003 · Cited by 44
“Moreover, among the angiotensin II receptor subtypes, angiotensin II receptor 1 was associated with increased type 1 collagen production, while angiotensin II receptor 2 had the inverse effect [80].”
BackgroundRecent advances in tumor microenvironment associated therapeutic strategies and evaluation models
Haider, T., Sandha, K. K., Soni, V., & Gupta, P. N. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111229 · Cited by 45
Mechanobiology of Autophagy: The Unexplored Side of Cancer
Hernández‐Cáceres, M. P., Munoz, L., Pradenas, J., Pena, F., Lagos, P., Aceitón, P., Owen, G. I., Morselli, E., Criollo, A., Ravasio, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.632956 · Cited by 46
“Another drug that is currently being studied in clinical trials is losartan, an angiotensin II receptor blocker, which reduces intratumoral interstitial fluid pressure in solid tumors [276].”
BackgroundRepurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
Hijazi, M. A., Gessner, A., & El‐Najjar, N. (2023) · Cancers · doi:10.3390/cancers15123199 · Cited by 46
Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499
Ando, H., Asai, T., Koide, H., Okamoto, A., Maeda, N., Tomita, K., Dewa, T., Minamino, T., & Oku, N. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.02.019 · Cited by 43
Saikawa, S., Kaji, K., Nishimura, N., Seki, K., Sato, S., Nakanishi, K., Kitagawa, K., Kawaratani, H., Kitade, M., Moriya, K., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.021 · Cited by 51
Wang, H., Mislati, R., Ahmed, R., Vincent, P., Nwabunwanne, S. F., Gunn, J. R., Pogue, B. W., & Doyley, M. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2684 · Cited by 43
Strittmatter, N., Richards, F. M., Race, A. M., Ling, S., Sutton, D., Nilsson, A., Wallez, Y., Barnes, J., Maglennon, G. A., Gopinathan, A., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04579 · Cited by 48
Liu, B., Liu, T., Liu, Y., Feng, X., Jiang, X., Long, J., Ye, S., Chen, D., Wang, J., & Yang, Z. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69178 · Cited by 50
“Studies have shown that CAFs can form a collagen-rich TME, thereby creating a stiff ECM, which compresses intratumoral blood vessels and aggravates hypoxia [29, 30].”
BackgroundNanomechanical properties of solid tumors as treatment monitoring biomarkers
Stylianou, A., Mpekris, F., Voutouri, C., Papoui, A., Constantinidou, A., Kitiris, E., Kailides, M., & Stylianopoulos, T. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.10.021 · Cited by 48
Self-citationTanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023) · Cancers · doi:10.3390/cancers15030724 · Cited by 46
Progress on the pathological tissue microenvironment barrier-modulated nanomedicine
Han, H., Xing, L., Chen, B., Liu, Y., Zhou, T., Wang, Y., Zhang, L., Li, L., Cho, C., & Jiang, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115051 · Cited by 45
Chemotherapy, immunotherapy, and targeted therapy for osteosarcoma: Recent advancements
Adewuyi, E. E., Chorya, H. P., Muili, A. O., Moradeyo, A. A., Kayode, A. T., Naik, A., Odedele, J. T., & Obasanjo, O. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104575 · Cited by 50
Zhu, Y., Yu, F., Tan, Y., Hong, Y. K., Meng, T., Liu, Y., Dai, S., Qiu, G., Yuan, H., & Hu, F. (2019) · Theranostics · doi:10.7150/thno.36334 · Cited by 43
“Both Tel and GLPM/Tel showed remarkable inhibitory effect on HUVEC tube formation at 2 μg/mL compared with the PBS group, which could prune tortuous and disordered vessels to reduce vessel hyperpermeability for improved blood perfusion in vivo [37, 38].”
Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma
Karimnia, V., Slack, F. J., & Celli, J. P. (2021) · Cancers · doi:10.3390/cancers13174354 · Cited by 47
“which downregulate TGF-β; thus, inhibiting collagen production [37,56].”
BackgroundZhang, B., Jiang, T., Tuo, Y., Jin, K., Luo, Z., Shi, W., Mei, H., Hu, Y., Pang, Z., & Jiang, X. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.007 · Cited by 41
Zhang, B., Shi, W., Jiang, T., Wang, L., Mei, H., Lu, H., Hu, Y., & Pang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.11546 · Cited by 41
“As PDGF-β signaling pathway was also involved in tumor ECM production [31], inhibiting PDGF-β pathway would disrupt ECM to a certain degree, which could decompress vessels and also contribute to tumor perfusion improvement [32].”
BackgroundBiomaterial-based platforms for modulating immune components against cancer and cancer stem cells
Desai, N., Hasan, U., Jeyashree, K., Mani, R., Chauhan, M. K., Basu, S. M., & Giri, J. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.03.004 · Cited by 43
Personalized In Vitro Cancer Modeling — Fantasy or Reality?
Bartlett, R. D., Everett, W., Lim, S., Natasha, G., Loizidou, M., Jell, G., Tan, A., & Seifalian, A. M. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.10.006 · Cited by 45
“The interstitial fluid pressure of the tumor is often raised and is believed to compress the vasculature, reducing perfusion [36,47].”
BackgroundYeo, D., Phillips, P. A., Baldwin, G. S., He, H. Z., & Nikfarjam, M. (2017) · International Journal of Cancer · doi:10.1002/ijc.30615 · Cited by 41
Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
Zhang, Y., Yang, C., Cheng, H., Fan, Z., Huang, Q., Yu, L., Fan, K., Luo, G., Jin, K., Wang, Z., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0551-7 · Cited by 45
“Preclinical studies concluded that it increased vascular perfusion, oxygen, and potentiates chemotherapy [62].”
BackgroundTumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy
Potiron, V. A., Clément-Colmou, K., Jouglar, E., Pietri, M., Chiavassa, S., Delpon, G., Paris, F., & Supiot, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.005 · Cited by 41
Recent advances in targeted therapy for pancreatic adenocarcinoma
Fang, Y., Yang, W., Niu, Y., & Sun, Y. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i4.571 · Cited by 47
Multifunctional Liposomes Remodeling Tumor Immune Microenvironment for Tumor Chemoimmunotherapy
Li, X., Luo, Y., Huang, Z., Wang, Y., Wu, J., & Zhou, S. (2023) · Small Methods · doi:10.1002/smtd.202201327 · Cited by 44
Emerging nanotechnological approaches to regulating tumor vasculature for cancer therapy
Wang, C., Xu, J., Zhang, Y., & Nie, G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.017 · Cited by 41
Targeting Cancer‐Associated Fibroblasts: Eliminate or Reprogram?
Yamazaki, M., & Ishimoto, T. (2025) · Cancer Science · doi:10.1111/cas.16443 · Cited by 46
“Currently, clinical trials are underway using compounds such as losartan and minnelide, which serve to inhibit the production and polymerization of collagen and hyaluronic acid [42, 43] (for further details, please refer to Section 6).”
Impact of renin‐angiotensin system blockade on clinical outcome in glioblastoma
Januel, É., Ursu, R., Alkhafaji, A., Marantidou, A., Doridam, J., Belin, C., Lévy-Piedbois, C., & Carpentier, A. F. (2015) · European Journal of Neurology · doi:10.1111/ene.12746 · Cited by 40
“Indeed, it was recently reported in animal models that Ang-II inhibitors could improve oxygen delivery at the tumour site [23], which is a critical factor for radiosensitivity [24].”
BackgroundQin, T., Xu, X., Zhang, Z., Li, J., You, X., Guo, H.-L., Sun, H., Liu, M., Dai, Z., & Zhu, H. (2020) · Nanotechnology · doi:10.1088/1361-6528/ab94dc · Cited by 41
“Recent studies have reported that SUN can not only reduce the production of new tumor blood vessels and inhibit the growth of tumor extracellular matrix components [18], but it can also remodel the immune-suppressive TME such as augmenting IFN-γ production of tumor-infiltrating T cells,reducing the level and function…”
BackgroundDe Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
“In vitro/ animal models Blockade of AT1R leading to impaired stromal collagen and hyaluronan production by CAFs; improved overall survival in orthotopic PC mouse models through enhanced tumor perfusion, oxygen, chemo- and nanotherapeutics delivery [56,57]”
BackgroundInfluentialDual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives
Toledo, B., Picon‐Ruiz, M., Marchal, J. A., & Perán, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415576 · Cited by 42
“Examples include, among others, the angiotensin inhibitor losartan [296] and enzymatic therapies such as PEGPH20, a pegylated hyaluronidase enzyme designed to degrade HA produced by CAFs in TME.”
BackgroundSchiffmann, L. M., Brunold, M., Liwschitz, M., Goede, V., Loges, S., Wroblewski, M., Quaas, A., Alakus, H., Stippel, D. L., Bruns, C. J., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.13 · Cited by 41
“05). www.bjcancer.com |DOI:10.1038/bjc.2017.13 605 decompression has previously been reported in response to significantly reduced intra-tumoural collagen content (Chauhan et al, 2013).”
BackgroundInfluentialSingh, A., Nunes, J. J., & Ateeq, B. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.011 · Cited by 45
“, 2013), which could be a possible reason for selecting Losartan over other ARBs for a pancreatic cancer clinical trial study (Chauhan et al., 2013).”
BackgroundInfluentialTumour tissue transport after intraperitoneal anticancer drug delivery
Carlier, C., Mathys, A., Jaeghere, E. A. D., Steuperaert, M., Wever, O. D., & Ceelen, W. P. (2017) · International Journal of Hyperthermia · doi:10.1080/02656736.2017.1312563 · Cited by 44
Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer
Polášek, M., Yang, Y., Schühle, D. T., Yaseen, M. A., Kim, Y. R., Sung, Y. S., Guimarães, A. R., & Caravan, P. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-08838-6 · Cited by 40
Zhang, Y., Liu, Y., Gao, X., Li, X., Niu, X., Yuan, Z., & Wang, W. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.04.022 · Cited by 39
Tumour vessel remodelling: new opportunities in cancer treatment
Ganß, R. (2020) · Vascular Biology · doi:10.1530/vb-19-0032 · Cited by 42
The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment
Tempest, R., Guarnerio, S., Maani, R., Cooper, J., & Peake, N. (2021) · Cancers · doi:10.3390/cancers13112788 · Cited by 41
“Changes in mechanical properties have been shown to influence drug delivery and immunotherapy interventions, with angiotensin receptor blockers such as losartan showing promise through the targeting of tension in the TME and promotion of vascular function [170,171].”
BackgroundLi, Z., Ning, F., Wang, C., Yu, H., Ma, Q., & Sun, Y. (2021) · Nanoscale · doi:10.1039/d1nr03387e · Cited by 46
Bhargava, A., Monteagudo, B., Kushwaha, P., Senarathna, J., Ren, Y., Riddle, R. C., Aggarwal, M., & Pathak, A. P. (2022) · Nature Methods · doi:10.1038/s41592-021-01363-5 · Cited by 42
“In solid tumors, these mechanisms are often hindered by the abnormal architecture of the vasculature and/or density of extracellular matrix components (e.g. collagen fibers) 47,48 .”
A non-equilibrium thermodynamic model for tumor extracellular matrix with enzymatic degradation
Xue, S.-L., Li, B., Feng, X., & Gao, H. (2017) · Journal of the Mechanics and Physics of Solids · doi:10.1016/j.jmps.2017.04.002 · Cited by 41
Zhou, K., Zhang, J., Wang, Q., Liu, W., Liu, J., Yao, L., Cai, M., Ni, S., Cai, Q.-Y., Wang, G., et al. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0058-y · Cited by 40
Shen, H., Gao, Q., Ye, Q., Yang, S., Wu, Y., Huang, Q., Wang, X., & Sun, Z. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s178585 · Cited by 38
“More recently, Los has exhibited remarkable effects in reducing collagen levels in solid tumors via an angiotensin II type I receptor, which mediates the downregulation of tumor TGF-β1.”
Background
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.